Last updated: May 25, 2026
This fixed-dose H. pylori regimen is typically commercialized as a branded combination product in the U.S. and is governed by a mix of drug-substance exclusivity, formulation patents, and method-of-treatment IP. For a clinical trials update plus market projections, a complete patent- and FDA-regulatory fact set is required (Orange Book listings, NDA/ANDA identifiers, clinical trial registrations, and any recent label or regulatory actions). No such identifying dataset for the specific combination product and its U.S. regulatory record is present here, so a complete and accurate update and projection cannot be produced.
What clinical trials are ongoing or recently completed for bismuth subsalicylate metronidazole tetracycline hydrochloride H. pylori?
Featured snippet answer: No sourceable clinical-trial status or endpoint results can be stated without the exact registered product (trial registry links and formulation identifiers).
Which trial endpoints matter for this regimen?
H. pylori programs typically report:
- Eradication rates (per-protocol and ITT)
- Resistance-linked outcomes (metronidazole and tetracycline resistance)
- Safety and tolerability (GI adverse events, C. difficile signal, photosensitivity)
- Compliance metrics and treatment duration adherence
What trial designs are common?
- Randomized comparisons vs clarithromycin-containing regimens
- Quadruple-therapy comparisons
- Resistance-guided studies based on local susceptibility patterns
How big is the market for H. pylori therapy using bismuth subsalicylate metronidazole tetracycline hydrochloride?
Featured snippet answer: A quantified market size and growth forecast require a defined payer/segment scope and the specific branded product(s) tied to this exact combination. No product identifiers or market datasets are provided, so no defensible revenue, TRx, or TAM/SAM/SOM projections can be produced.
Market segmentation that drives revenue models
- Country (U.S. vs EU vs major APAC markets)
- Setting (primary care vs GI specialty)
- Line of therapy (first-line eradication vs salvage)
- Resistance profile prevalence (metronidazole resistance rates, tetracycline susceptibility assumptions)
- Formulation channel (hospital dispensing vs retail)
Key demand drivers and constraints
- H. pylori diagnosis rates and test-and-treat strategies (endoscopy use vs noninvasive testing)
- Antibiotic stewardship and resistance mitigation policies
- Generic entry timing, PBM contracting, and reimbursement
When does exclusivity expire for bismuth subsalicylate metronidazole tetracycline hydrochloride in the U.S.?
Featured snippet answer: Exclusivity timelines require the NDA/Orange Book listing(s) for the exact combination product and the reference drug in which it is listed. No NDA/Orange Book record is provided, so expiration cannot be stated accurately.
What exclusivity layers usually govern this category?
- 5-year new chemical entity or new formulation exclusivity
- 3-year new clinical investigation exclusivity
- Patent protection (composition, formulation, and method-of-treatment)
- Market exclusivity impacts from FDA labeling history and postmarketing commitments
What does “loss of exclusivity” mean in practice?
- Patent term expiration (composition and formulation patents)
- Regulatory exclusivity expiration (timing for generic/AB-rated ANDA entry)
- Orange Book “blocking” patents that prevent immediate generic launch
What patents protect bismuth subsalicylate metronidazole tetracycline hydrochloride?
Featured snippet answer: A patent estate map requires:
- Orange Book patent list(s) for the specific U.S. combination product
- Patent numbers, assignees, and expiration dates
None of those records are present here.
Patent categories you typically see
- Composition claims covering the combination and ratios
- Formulation claims (coated granules/capsules, stability, dissolution profiles)
- Method-of-use claims (treatment regimens, dosing schedules, H. pylori eradication)
- Manufacturing process claims (granulation, blending order, sterilization or drying steps if relevant)
How to measure patent strength for this regimen
- Number of listed Orange Book patents per listed drug
- Remaining claims lifetime vs likely generic design-arounds
- Litigation history and whether patents were upheld
Which companies are challenging the product via Paragraph IV filings?
Featured snippet answer: Paragraph IV litigation and filings require PACER/filing notice datasets tied to the specific NDA. No filing list is provided, so this cannot be answered accurately.
What to look for in court dockets
- Case caption and patent numbers asserted
- Settlement terms (e.g., agreed design-around timelines)
- FDA approval dates tied to “section viii” and “section viii carve-outs” if present
What is the Orange Book status of bismuth subsalicylate metronidazole tetracycline hydrochloride?
Featured snippet answer: Orange Book status cannot be stated without the specific FDA listing(s).
What an Orange Book table should include
- Listed drug name and strength
- Patent number
- Patent expiration and regulatory exclusivity expiration
- Patent type (composition, method, formulation, use)
- Applicant/holder and licensees where listed
What formulations are protected for this regimen and how do generic versions design around them?
Featured snippet answer: Formulation protection requires the actual patent claims and the approved dosage form.
Typical design-around vectors
- Different excipient systems
- Alternate release profiles (if applicable)
- Different dosing units while staying within the approved ratio
- Manufacturing process changes to avoid process claims
Bioequivalence and substitution issues
- Bioequivalence study requirements depend on formulation differences
- Interchangeability and pharmacy substitution rules vary by jurisdiction
What patent litigation affects competitive entry for this combination?
Featured snippet answer: Litigation status requires case numbers and asserted patents. No litigation dataset is provided, so no accurate “what affects entry” analysis can be produced.
Litigation outcomes that move launch dates
- Injunctions and consent decrees
- Findings on infringement vs invalidity
- Design-around approvals and stipulations tied to noninfringement
How does this regimen compare with clarithromycin or rifabutin-based H. pylori therapies on efficacy and resistance?
Featured snippet answer: A comparative effectiveness analysis requires a defined reference therapy and a cited evidence base. No clinical guideline set or trial dataset is provided.
Resistance-driven selection
- Metronidazole: resistance often reduces eradication rates if not paired with adequate regimen features
- Tetracycline: lower resistance in many settings, but global emergence changes outcomes
- Clarithromycin: resistance frequently drives reduced success rates
Stewardship and guideline shifts
- Local resistance thresholds and guideline updates
- Treatment duration changes from 10-14 days historically to other durations in some jurisdictions
How many patients are treated annually and what is the demand for first-line vs salvage eradication?
Featured snippet answer: Patient numbers and treatment mix cannot be quantified without epidemiology and claims datasets tied to the product category and geography.
Inputs usually used
- H. pylori prevalence by country
- Proportion diagnosed and treated
- Recurrence and salvage rates
- Adherence rates and discontinuation
What generic entry risks exist for bismuth subsalicylate metronidazole tetracycline hydrochloride?
Featured snippet answer: Generic entry risk hinges on:
- Remaining patent term on Orange Book blocking patents
- Ongoing litigation posture
- Regulatory exclusivity expiration
No Orange Book or litigation dataset is provided here, so risk cannot be quantified.
Launch scenario framework
- “First-to-file” Paragraph IV with 30-month stay
- Design-around leading to faster approval
- Settlement forcing delayed entry at a specified date
How do settlements and exclusivity agreements change the market outlook?
Featured snippet answer: Settlement and “entry-date” impacts require the exact settlement terms from dockets and FDA approvals. No settlement data is available.
Common settlement components
- Carve-outs to specific strengths or dosage forms
- Agreed entry dates
- Dismissal of certain patents and continued litigation on others
Regulatory questions: FDA pathway, labeling, and postmarketing changes
Featured snippet answer: FDA pathway specifics for the exact combination product cannot be stated without NDA identifiers and label revision history.
What label terms can move demand
- Indications (H. pylori eradication protocols vs broader GI use)
- Dosing duration and combination schedule changes
- Safety warnings tied to antibiotic class risks
Key Takeaways
- A clinical trials update and a market projection for bismuth subsalicylate + metronidazole + tetracycline hydrochloride require product-specific FDA identifiers, Orange Book patent listings, and trial registry records.
- No such product-identifying dataset is included here, so exclusivity, patent protection scope, Paragraph IV challenges, litigation posture, and revenue forecast cannot be produced accurately.
FAQs
- What is the latest FDA label status for bismuth subsalicylate metronidazole tetracycline hydrochloride in H. pylori?
- Are there current Phase 3 trials comparing this regimen to clarithromycin-based triple therapy?
- Do metronidazole and tetracycline resistance patterns change expected eradication rates for this combination?
- What Paragraph IV notices have been filed against the U.S. NDA/combination product containing bismuth subsalicylate, metronidazole, and tetracycline hydrochloride?
- How soon can generic manufacturers enter once Orange Book blocking patents expire for this H. pylori regimen?
References
- No sources were provided or identifiable for this specific product combination’s FDA listing, trial registrations, or patent estate.
